Although we can offer shares at any price we want, anyone with serious money will know they're getting hosed if we don't get some serious catalysts in the future, or do some financial engineering such that we don't get as great a deal (not that that's bad).
Example: We organically rise in price post successful tender exchange in anticipation of this plan. Let' say that get's us to 20 cents. Good, not crazy. We do a 1/10 split so new investors don't feel hosed. We successfully raise $20M for 10million new shares. The new company has $20M in capital, 25M shares O/S, 3/5 of which is us current shareholders, a 50M share A/S for future raises and to deal with the "controlled leak out" to pay back the legacies. This allows us to pursue success in trials and attract better financing. That's a good future on a national exchange, really all we can hope for, a stable chance at getting rewarded for changing the world of medicine.
Remember, in tandem with this pursuit, and a feeling of hope, more good things are going to continue to happen with MANF etc. Again, by the July uplist timeframe, successful CDNF data could be hot off the presses and people could be foaming at the mouth for AMBS. That will allow us to sell shares at a greater value ratio to current share holders and limit dilution while increasing runway.